Dataset opportunity
Hannonpharmalink — 监管记录数据集机会
Hannonpharmalink 持有的中等监管记录数据集，可用于监管 RAG 和合规性助手。
Score
70
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
全球制药物流市场规模在 2025 年为 805.6 亿美元，预计将呈现 7.90% 的复合年增长率（来源：Spherical Insights LLP）
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📣Press / announcement
投资于带集成跟踪的专业冷藏车队
source ↗
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
mobility
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
RegTech 和合规性 AI 供应商
Hannonpharmalink 提供文本模态的监管记录数据集，该数据集汇集了来自 API、事件流、IoT 数据和正式监管申报的丰富组合。这些数据提供了对制药物流运营的细粒度、基于证据的视图，使其特别适合监管 RAG 用例，能够让 AI 从复杂的多格式源材料中检索和综合精确的合规性和运营答案。
全球制药物流市场在 2025 年的价值为 805.6 亿美元，预计将以 7.90% 的复合年增长率增长。[2] 该数据集的价值因其稀有的敏感制药供应链信息和温控物流记录的组合而得到提升，这些记录受严格的 GDP 合规性约束。虽然访问需要 Hannon Group 的集团级别批准，但数据的深度及其直接适用于高价值的 AI 合规自动化，使其成为成熟买家的有吸引力的资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据包括敏感的制药供应链信息；温控物流记录受严格的监管合规性（GDP）约束；作为更大的 Hannon Group 的一部分，需要集团级别的数据共享批准。· 公司：Hannon Group 的子公司。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Hannonpharmalink 持有一个专有数据集，详细说明了制药运输的完整生命周期，包括监管合规记录、实时IoT 传感器数据和端到端事件流。对于 RegTech 和合规性 AI 供应商来说，这是一个稀有的地面实况数据源，对于训练能够自动化审计并确保GDP 合规性的监管 RAG 模型至关重要。在年增长率接近 8% 的制药物流市场中，该数据集通过实现下一代合规解决方案提供了显著的竞争优势。
See dimension details ↓- ICP Audit100
✓ 良好目标 — 这是一个完美的目标：一家专业的物流中小企业，拥有真实的运营业务和自己的车队，作为其核心运输服务的副产品生成专有、休眠数据。
- Deep Qualification90
⚠ 需要审查 — Hannonpharmalink 是一个物流服务提供商，而不是数据销售商；数据可能归其客户所有，是其受监管运输业务的合理但高度受限的副产品。[数据归公司客户所有；许可受限]
- Dataset Specificity90
占主导地位的“监管”，行业 mobility，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand80
AI 买家需求强劲，这得益于在快速增长的制药物流市场（复合年增长率为 7.90%）中实现合规自动化和提高效率的需求。[2]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility32
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，Hannon Group 的子公司
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 种证据类型，4 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=拥有，许可=gdpr_敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
Hannon Group 的子公司
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据胃口信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 超出已货币化的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
API access
这些证据指向处理活性药物成分的质量管理系统的文档，这是任何服务于受监管制药供应链的供应商的关键组成部分。
IoT / sensor data
该公司通过其实时温度监控和 GPS 跟踪系统生成有价值的时间序列数据，这对于冷链验证和风险管理应用至关重要。
Regulatory records
这个基于文本的数据集包含证明符合药品良好分销规范 (GDP) 所必需的可追溯性记录和审计跟踪，直接为监管报告和人工智能驱动的合规模型提供支持。
Event streams
持有者捕获详细的事件流，提供对货物运输的端到端可见性，为供应链优化模型提供关于运输时间和物流交接的细粒度数据。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Coverage
Scanned sources
Deliverable
Premium dataset report
Hannonpharmalink Regulatory Records — a Moderate regulatory records dataset (Text modality) in the mobility domain. Primary AI use-case: Regulatory RAG. Market signal: Global pharmaceutical logistics market size was valued at USD 80.56 billion in 2025, projected to exhibit a CAGR of 7.90% (source: Spherical Insights LLP). Investment score 70.0/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Paua — 移动遥测数据集机会
View opportunity →工业Valaratomics — 法规记录数据集机会
View opportunity →移动Trucksters — 移动遥测数据集机会
View opportunity →